Ipilimumab Combination Appears Ineffective for Treatment of SCLC

Share this content:
The addition of ipilimumab to etoposide and a platinum agent failed to prolong overall survival, when contrasted with chemotherapy only.
The addition of ipilimumab to etoposide and a platinum agent failed to prolong overall survival, when contrasted with chemotherapy only.

The addition of ipilimumab to etoposide and a platinum agent failed to prolong overall survival, when contrasted with chemotherapy only, for patients with extensive-stage small cell lung cancer (SCLC), a study published in the Journal of Clinical Oncology has shown.1

Patients with extensive-stage SCLC have poor survival outcomes despite the use of etoposide and a platinum agent as first-line therapy; researchers evaluated the efficacy and safety of adding ipilimumab to that regimen in newly diagnosed patients in this phase 3 trial.

For this double-blind study, investigators enrolled 1132 patients and randomly assigned them 1:1 to receive chemotherapy with etoposide and cisplatin or carboplatin, plus ipilimumab 10 mg/kg or placebo every 3 weeks for a total of 4 doses.

Among the 954 patients who received at least 1 dose of study therapy, median overall survival was 11.0 months with chemoimmunotherapy, compared with 10.9 months for chemotherapy plus placebo (hazard ratio, 0.94; 95% CI, 0.81-1.09; P = .3775).

Median progression-free survival was 4.6 months and 4.4 months for chemotherapy plus ipilimumab and chemotherapy plus placebo, respectively (hazard ratio, 0.85; 95% CI, 0.75-0.97).

Treatment-related adverse events were similar between the 2 groups, though diarrhea, rash, and colitis occurred more frequently in the ipilimumab group.

RELATED: TAS-102 Ineffective for Treatment of Small Cell Lung Cancer

Eighteen percent of patients in the ipilimumab arm discontinued treatment due to toxicities, versus 2% in the placebo arm. Five patients treated with ipilimumab died; 2 died in the placebo group; these deaths were treatment-related.                            

Reference

  1. Reck M, Luft A, Szczesna A, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016 Jul 25. doi: 10.1200/JCO.2016.67.6601 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters